Saturday, July 11, 2026

pharma · Renal Impairment · Osteoarthritis, Knee / Osteoarthritis, Hip

Tanabe Pharma

Tanabe Pharma is a pharma organization headquartered in Osaka, JP. Primary therapeutic focus areas include Renal Impairment, Osteoarthritis, Knee / Osteoarthritis, Hip. NovaPharmaNews links 4 clinical program(s), 0 drug

Osaka, JP HQ
1678 Founded
104 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Osaka, JP
Founded
1678
Employees
104
Programs
4
Drugs
1
Patents
0
Clinical program

MT-1186

Phase 3 · small molecule · ALS

MT-1186 for ALS is a Phase 3 program (small_molecule) at Tanabe Pharma with 1 ClinicalTrials.gov record(s).

← All Tanabe Pharma projects Phase 3 small molecule terminated

Internal code MT-1186-A04

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Tanabe Pharma
Phase
Phase 3
Modality
small_molecule
Indication
ALS
Status
terminated
Trials
1

Clinical trials